# ELIQUIS (APIXABAN) Regulatory Post-Marketing Surveillance In Clinical Practice for Venous Thromboembolism (VTE) Treatment and Prevention Of Recurrent VTE

> **NCT02836457** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 1134 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02836457
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-01
- **Primary completion:** 2018-07-31
- **Final completion:** 2018-07-31
- **Target enrollment:** 1134 (ACTUAL)
- **Last updated:** 2022-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02836457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02836457, "ELIQUIS (APIXABAN) Regulatory Post-Marketing Surveillance In Clinical Practice for Venous Thromboembolism (VTE) Treatment and Prevention Of Recurrent VTE". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02836457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*